Inaspir

Salmeterol, the active ingredient in Inaspir, is a long‑acting β2‑adrenergic agonist (LABA) presented as an inhalation for inhalation use. It provides prolonged bronchodilation for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adult patients. It is indicated for maintenance therapy and is administered via a metered‑dose inhaler designed for precise dose delivery.

GNH USA supplies Inaspir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across all markets.

Salmeterol is a long‑acting β2‑adrenergic agonist used in the management of obstructive airway diseases.

Asthma: improves bronchodilation and reduces symptoms in patients with persistent asthma when used as maintenance therapy. COPD: provides sustained bronchodilation to improve airflow and decrease exacerbation frequency in COPD patients. Maintenance therapy: used in combination with inhaled corticosteroids to achieve better asthma control and reduce the risk of severe attacks. Exercise‑induced bronchoconstriction: helps prevent bronchospasm triggered by physical activity in asthma patients.

Common and serious adverse reactions have been reported with salmeterol inhalation.

Common Side Effects: - Throat irritation - Cough - Headache - Tremor

Serious or Rare Side Effects: - Paradoxical bronchospasm - Tachyarrhythmia - Severe allergic reaction (anaphylaxis)

When prescribing Inaspir, clinicians should consider several safety measures. - Cardiovascular assessment: evaluate patients with known heart disease before initiating therapy. - Monitor asthma control: watch for worsening symptoms or reduced response. - Use with inhaled corticosteroid: combine to lower risk of asthma‑related death. - Hypersensitivity: discontinue if patient experiences allergic reactions. - Pregnancy and lactation: assess risk–benefit; limited data available. - Store at room temperature: keep in original container, protect from moisture and heat.

Salmeterol may interact with other medicines, requiring caution.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors: risk of enhanced cardiovascular effects. - Diuretics: can increase risk of hypokalemia when combined with salmeterol.

Moderate Interactions (Monitor Closely): - Inhaled corticosteroids: may increase systemic exposure; monitor for side effects. - Theophylline: salmeterol may raise theophylline plasma levels; adjust dose if needed. - CYP3A4 inhibitors: may elevate salmeterol concentrations; observe for increased adverse effects.